Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ENDRA Life Sciences (NDRA) Change in Receivables (2017 - 2018)

ENDRA Life Sciences has reported Change in Receivables over the past 2 years, most recently at -$12275.0 for Q4 2018.

Quarterly Change in Receivables fell 279.2% to -$12275.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$12275.0 through Sep 2019, down 200.0% year-over-year, with the annual reading at -$6850.0 for FY2018, 200.0% down from the prior year.
Change in Receivables was -$12275.0 for Q4 2018 at ENDRA Life Sciences, down from $505.0 in the prior quarter.
Over five years, Change in Receivables peaked at $6850.0 in Q4 2017 and troughed at -$12275.0 in Q4 2018.